靶向治疗高危胃肠道间质瘤的临床疗效  

Clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor

作　　者：闵凯[1] 曹峰瑜[1] 任骏[1] 吴彪[1] 肖新波[1] 

机构地区：[1]湖北省武汉市第一医院胃肠外科二,湖北武汉430022

出　　处：《中国普通外科杂志》2016年第10期1408-1411,共4页China Journal of General Surgery

摘　　要：目的：探讨应用伊马替尼治疗高危胃肠道间质瘤（GIST）的临床疗效。方法：回顾性分析2010年1月-2015年6月收治的56例接受伊马替尼靶向治疗的高危GIST患者临床资料，并对疗效进行分析。结果：19例无手术切除机会的患者经伊马替尼（400mg／d）治疗6-8个月后，无完全缓解（CR）者，部分缓解（PR）14例，疾病稳定（SD）4例，疾病进展（PD）1例；7例（36.8％）PR患者获得手术切除机会。35例行手术切除后服用伊马替尼（400mg／d）1年，随访3例复发，1年复发率8．6％；2例终断服药，无法评估疗效。结论：伊马替尼治疗GIST疗效肯定，对于高危GIST患者，术前新辅助化疗能让无法手术切除的肿瘤获得手术机会，术后辅助化疗可能提高无瘤生存率，不良反应较轻能够耐受。Objective： To explore the clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor （GISTS）. Methods, The clinical data of 56 patients with high risk GIST undergoing imatinib targeted therapy from January 2010 to June 2015 were reviewed, and the therapeutic efficacy was analyzed. Results： Nineteen patients, who had no chance of surgical resection, received imatinih （400 mg/d） therapy for 6 to 8 months, and of them, none achieved complete response （CR）, 14 cases obtained partial response （PR）, 4 cases had stable disease （SD）, and one case presented progressive disease （PD）; 7 PR cases （36.8%） obtained a chance for tumor resection. Thirty-five patients received imtinib （400 mg/d） treatment for one year after surgical resection, and of them, recurrence occurred in 3 cases （8.6%） during follow-up and the one-year recurrence rate was 8.6%; 2 cases did not continue to take the medication and their results could not be determined. Conclusion： Imatinib has significant efficacy in GIST patients, and in those with high risk GIST, its preoperative neoadjuvant chemotherapy may offer a chance of surgical resection for the unresectable tumors, and its postoperative adjuvant chemotherapy may improve the tumor-free survival with tolerable adverse effects.

关 键 词：胃肠道间质肿瘤 原癌基因蛋白质类c-kit 蛋白激酶抑制剂 分子靶向治疗 

分 类 号：R735.3[医药卫生—肿瘤]